---
title: A Clinical Study of Chinese Herbal Formula TJAOA103 in Treating Genitourinary Syndrome of Menopause
nct_id: NCT07160127
overall_status: NOT_YET_RECRUITING
phase: EARLY_PHASE1
sponsor: Tongji Hospital
study_type: INTERVENTIONAL
primary_condition: Genitourinary Syndrome of Menopause (GSM)
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07160127.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07160127"
ct_last_update_post_date: 2025-09-17
last_seen_at: "2026-05-12T06:16:37.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Clinical Study of Chinese Herbal Formula TJAOA103 in Treating Genitourinary Syndrome of Menopause

**Official Title:** The Efficacy and Safety of Chinese Herbal Formula TJAOA103 for the Treatment of Genitourinary Syndrome of Menopause: A Prospective and Single-Arm Study

**NCT ID:** [NCT07160127](https://clinicaltrials.gov/study/NCT07160127)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Phase:** EARLY_PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 113
- **Lead Sponsor:** Tongji Hospital
- **Conditions:** Genitourinary Syndrome of Menopause (GSM)
- **Start Date:** 2025-09-15
- **Completion Date:** 2027-09-15
- **CT.gov Last Update:** 2025-09-17

## Brief Summary

The goal of this clinical trial is to learn if Chinese herbal formula TJAOA103 works to treat genitourinary syndrome of menopause (GSM). It will also learn about the safety of TJAOA103. The main questions it aims to answer are:

1. Does TJAOA103 alleviate the symptoms of GSM in participants or have any other benefits?
2. What medical problems do participants have when taking TJAOA103? Researchers will conduct a pre-post comparison to see if TJAOA103 works to treat GSM.

Participants will:

1. Take TJAOA103 twice daily for 4 to 12 weeks.
2. Complete the tests and/or questionnaires on schedule through online follow-up or outpatient visits.
3. Record their use of TJAOA103 and any adverse events.

## Detailed Description

Genitourinary syndrome of menopause (GSM) refers to a collection of symptoms and signs such as atrophy of the genital and urinary tracts and sexual dysfunction in women during the menopausal transition and postmenopausal period due to the decline in estrogen and other sex hormone levels. The primary pathogenesis is rooted in ovarian aging. GSM not only causes persistent discomfort and increases the risk of infections but also significantly impairs sexual function and self-esteem in middle-aged and older women. Furthermore, the failure of ovarian hormone function will markedly elevate the risk of aging-related diseases such as cardiovascular events, Alzheimer's disease, and osteoporosis in these patients, shortening their healthspan and increasing all-cause mortality. Therefore, timely intervention for GSM is crucial.

At present, vaginal moisturizers, lubricants, and vaginal estrogen preparations are commonly used in clinical practice to alleviate the symptoms of GSM. Vaginal moisturizers and lubricants help protect the vaginal epithelium and maintain an acidic vaginal environment, but may cause vaginal burning, infections, or allergic reactions. Vaginal estrogen preparations exert their effects on estrogen receptors within the genitourinary system, yet the long-term safety remains uncertain. Ospemifene, a selective estrogen receptor modulator, is another treatment option; however, its weak estrogenic effects may pose risks of thrombosis or endometrial thickening with prolonged use. In addition, laser therapy has also been employed for GSM, but carries potential safety risks including vaginal burns, scarring, and chronic pain.

Traditional Chinese medicine (TCM) possesses distinctive advantages in anti-aging strategies, addressing both symptoms and root causes with commendable safety profiles, thereby rendering it particularly appropriate for middle-aged and elderly populations. Numerous studies have demonstrated the effectiveness of TCM in the management of GSM-related conditions, such as postmenopausal vaginal dryness, atrophic vaginitis, and menopausal urethral syndrome. However, due to the limited understanding of the disease, existing TCM prescriptions have lacked specificity for GSM and often rely on empirical combinations without solid scientific foundation. To solve this problem, we have invented a novel TCM formula, Tongji Anti-Ovarian Aging 103 (TJAOA103). First, we performed an extensive literature retrieval to collect TCM prescriptions effective in alleviating GSM-associated symptoms. Using the TCM Inheritance Support System and the TCM Systems Pharmacology Database and Analysis Platform, we screened out a variety of candidate Chinese herbs and combinations with potential therapeutic effects on GSM, based on its pathogenesis. Then, a panel of senior experts in gynecology, TCM, and pharmacy thoroughly discussed the pharmacological actions, synergistic effects, contraindications, and dosages of these herbs, and developed the initial formula of TJAOA103. Subsequently, we utilized multiple models to verify the safety and effectiveness of TJAOA103, and further optimized the formulation.

This is a prospective, single-arm clinical study designed to evaluate the safety and efficacy of the TCM formula TJAOA103 in women diagnosed with GSM. Using a pre-post analysis, we will assess the improvements in clinical symptoms, signs, sexual function, genitourinary health, and quality of life in participants with GSM following TJAOA103 administration to provide a safe and reliable novel therapeutic strategy for this population.

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 70 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Females aged 45-70 years during the menopausal transition or postmenopausal period.
2. Presence of at least one moderate-to-severe (score ≥ 2) symptom of GSM, including vulvovaginal dryness, or vulvovaginal itching/irritation, or vulvovaginal burning/pain, or dyspareunia, or dysuria/urinary frequency/urgency.
3. Willing to participate in this trial and sign a written informed consent form.

Exclusion Criteria:

1. Acute or recurrent genitourinary infection.
2. Acute or chronic dermatosis of the vulva or vagina.
3. A grade 3 or higher degree of prolapse according to the Pelvic Organ Prolapse Quantification (POP-Q) system.
4. Unexplained abnormal uterine bleeding.
5. Ovarian/adnexal mass ≥ 4 cm, or adenomyosis, or adenomyoma/uterine myoma ≥ 4 cm.
6. Breast Imaging Reporting and Data System (BI-RADS) classification of breast ultrasound ≥ 4.
7. Presence of precancerous lesions or diagnosed malignancy.
8. Liver or kidney function indicators (ALT, AST, Urea, Cr) exceeding the upper limits of reference ranges upon repeated testing.
9. Severe primary diseases of the nervous, circulatory, respiratory, digestive, urinary or hematopoietic systems; or mental diseases;
10. Known allergy to any specific ingredient of the trial drugs.
11. Systemic hormone therapy within the past 2 months.
12. Application of vaginal moisturizers, lubricants, hormone preparations, or alternative therapies for GSM within the past month.
13. Current participation in another clinical trial or participation in another trial within the past month.
14. Unwillingness to discontinue the use of moisturizers, lubricants, or any form of hormonal drugs during the trial.
15. Other conditions deemed unsuitable for participation by the investigators.
```

## Arms

- **TJAOA103** (EXPERIMENTAL) — Once enrolled, participants will be administered TJAOA103 for 4 to 12 weeks.

## Interventions

- **TJAOA103** (DRUG) — Once enrolled, participants will be administered TJAOA103 for 4 to 12 weeks. TJAOA103 should be taken orally twice a day, one sack each time. Dissolve it in about 200 mL of warm water and drink it all. Participants can take it half an hour before breakfast in the morning and half an hour before bedtime in the evening.

## Primary Outcomes

- **severity of the most bothersome symptom (MBS)** _(time frame: From enrollment to the end of treatment at 4 or 12 weeks)_ — The MBS is derived from a selected list of common GSM symptoms, including vulvovaginal dryness, vulvovaginal itching/irritation, vulvovaginal burning/pain, dyspareunia, and dysuria/urinary frequency/urgency. At baseline, participants will be instructed to rate the severity of each symptom as absent (0), mild (1), moderate (2), or severe (3). They will then be asked to select a single MBS among those symptoms they classify as moderate or severe (i.e., a score ≥ 2). The MBS will be tracked through to the end of treatment, and the changes in its severity will be used to assess symptomatic improvement.

## Secondary Outcomes

- **total score of GSM symptoms** _(time frame: From enrollment to the end of treatment at 4 or 12 weeks)_
- **score for a specific GSM symptom** _(time frame: From enrollment to the end of treatment at 4 or 12 weeks)_
- **Vaginal Health Index Score (VHIS)** _(time frame: From enrollment to the end of treatment at 4 or 12 weeks)_
- **vaginal pH** _(time frame: From enrollment to the end of treatment at 4 or 12 weeks)_
- **Female Sexual Function Index-6 (FSFI-6)** _(time frame: From enrollment to the end of treatment at 4 or 12 weeks)_
- **Overactive Bladder Syndrome Score (OABSS)** _(time frame: From enrollment to the end of treatment at 4 or 12 weeks)_
- **score of International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)** _(time frame: From enrollment to the end of treatment at 4 or 12 weeks)_
- **score of Menopause-Specific Quality of Life Questionnaire (MENQOL)** _(time frame: From enrollment to the end of treatment at 4 or 12 weeks)_

## Locations (1)

- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.tongji hospital, tongji medical college, huazhong university of science and technology|wuhan||china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07160127.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07160127*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*